Select Language
FREE MEMBERSHIP DONATE NOW
Select Page

2020 Research Program

The principal goal of the Alport Syndrome Foundation, Inc. (ASF) is to find novel treatments to prevent kidney failure and hearing loss in all patients with Alport syndrome. The deadline for submission of a 2020 Research Program Letter of Intent was February 7th. Thank you to all those who submitted. We look forward to sharing this Annual Research Program opportunity again in late 2020/early 2021.

Application Focus

  • Identification and investigation of target pathways in disease progression
  • Development of means to improve early-stage, definitive, and predictive diagnosis
  • Repurposing of an FDA-approved drug to improve the current standard of care
kidney-health

Program Funding

  • At least one research project will be selected for a grant totaling US $125,000 delivered over a one- to two-year timeframe
  • Early stage investigators are encouraged to apply
  • Investigators focusing on historically understudied fields such as hearing loss in Alport syndrome and/or Alport syndrome in women are encouraged to apply
  • There are no geographical limitations of this funding

Process

Letters of intent (LoIs) will be evaluated by an independent peer review process. LoIs should be no longer than 2 pages in length and must be in accordance with the instructions. Authors of the LoIs found to have the best merit for funding will be invited to submit a full proposal application 10–15 pages in length for further independent peer review. Final grant recipients will be selected from this pool and notified in June 2020.

 

View Archived 2020 LOI Guidlines & Requirements

Deadline

The deadline for submission of a 2020 Research Program LoI has passed. Thank you to all those who submitted. We look forward to sharing this Annual Research Program opportunity again in late 2020/early 2021.

 

View Previously Funded Projects

 

For additional information contact:

André Weinstock, PhD, MSAS
Research Committee Chair
Alport Syndrome Foundation, Inc.
[email protected]

Select Language
X